Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

A Phase 3 study of Adjuvant Selpercatinib in lung cancer

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC 

For more information:

https://clinicaltrials.gov/ct2/show/NCT04819100?term=NCT04819100&draw=2&rank=1